WO2008073653A3 - Il- 17b for use in wound healing - Google Patents

Il- 17b for use in wound healing Download PDF

Info

Publication number
WO2008073653A3
WO2008073653A3 PCT/US2007/084151 US2007084151W WO2008073653A3 WO 2008073653 A3 WO2008073653 A3 WO 2008073653A3 US 2007084151 W US2007084151 W US 2007084151W WO 2008073653 A3 WO2008073653 A3 WO 2008073653A3
Authority
WO
WIPO (PCT)
Prior art keywords
wound healing
pharmaceutical composition
present
chondrocytes
parental
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/084151
Other languages
French (fr)
Other versions
WO2008073653A2 (en
Inventor
Emma E Moore
Harald S Haugen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Priority to EP07871415A priority Critical patent/EP2089050A2/en
Priority to JP2009536488A priority patent/JP2010509364A/en
Priority to CA002669109A priority patent/CA2669109A1/en
Publication of WO2008073653A2 publication Critical patent/WO2008073653A2/en
Publication of WO2008073653A3 publication Critical patent/WO2008073653A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

IL-17B is known to stimulate the proliferation of chondrocytes, bone, and is highly expressed in nervous tissue, resulting in repair of diseased tissue. When IL-17B is absent a marked negative effect on wound healing is noted. The present invention comprises providing IL-17B, by topical, parental, or other administration means, in order to accelerate the wound healing process. The present invention further encompasses a pharmaceutical composition and formulations thereof that utilize IL-17B, either alone or in combination with other cytokines or growth factors known to aid wound healing. The invention also contemplates methods of treating wounds in patients using this pharmaceutical composition.
PCT/US2007/084151 2006-11-08 2007-11-08 Il- 17b for use in wound healing Ceased WO2008073653A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07871415A EP2089050A2 (en) 2006-11-08 2007-11-08 Il- 17b for use in wound healing
JP2009536488A JP2010509364A (en) 2006-11-08 2007-11-08 IL-17B for use in wound healing
CA002669109A CA2669109A1 (en) 2006-11-08 2007-11-08 Il-17b for use in wound healing

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86486706P 2006-11-08 2006-11-08
US60/864,867 2006-11-08

Publications (2)

Publication Number Publication Date
WO2008073653A2 WO2008073653A2 (en) 2008-06-19
WO2008073653A3 true WO2008073653A3 (en) 2008-08-07

Family

ID=39415331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/084151 Ceased WO2008073653A2 (en) 2006-11-08 2007-11-08 Il- 17b for use in wound healing

Country Status (4)

Country Link
EP (1) EP2089050A2 (en)
JP (1) JP2010509364A (en)
CA (1) CA2669109A1 (en)
WO (1) WO2008073653A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2842337C (en) * 2011-07-28 2020-02-18 Ian S. Zagon Methods and compositions for treatment of epithelial wounds in diabetic subjects
US20220281967A1 (en) * 2019-08-02 2022-09-08 Orega Biotech Novel il-17b antibodies

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049310A1 (en) * 1997-04-25 1998-11-05 Zymogenetics, Inc. Mammalian cytokine-like factor 7
WO1999003982A1 (en) * 1997-07-16 1999-01-28 Human Genome Sciences, Inc. Interleukin-20
WO2000061754A2 (en) * 1999-04-09 2000-10-19 Curagen Corporation Human proteins and polynucleotides encoding them
WO2001046420A2 (en) * 1999-12-23 2001-06-28 Genentech, Inc. Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
WO2001064240A2 (en) * 2000-02-29 2001-09-07 Zymogenetics, Inc. Methods for promoting production of myelin by schwann cells
WO2002076386A2 (en) * 2001-03-26 2002-10-03 Zymogenetics, Inc. Method of inducing proliferation of retinal stem cells
US20040248097A1 (en) * 2003-05-23 2004-12-09 Ming-Shi Chang Interleukin-20 variants and promoters
WO2007019453A2 (en) * 2005-08-04 2007-02-15 Zymogenetics, Inc. Treatment of wounds using il-17b

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049310A1 (en) * 1997-04-25 1998-11-05 Zymogenetics, Inc. Mammalian cytokine-like factor 7
WO1999003982A1 (en) * 1997-07-16 1999-01-28 Human Genome Sciences, Inc. Interleukin-20
WO2000061754A2 (en) * 1999-04-09 2000-10-19 Curagen Corporation Human proteins and polynucleotides encoding them
WO2001046420A2 (en) * 1999-12-23 2001-06-28 Genentech, Inc. Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
WO2001064240A2 (en) * 2000-02-29 2001-09-07 Zymogenetics, Inc. Methods for promoting production of myelin by schwann cells
WO2002076386A2 (en) * 2001-03-26 2002-10-03 Zymogenetics, Inc. Method of inducing proliferation of retinal stem cells
US20040248097A1 (en) * 2003-05-23 2004-12-09 Ming-Shi Chang Interleukin-20 variants and promoters
WO2007019453A2 (en) * 2005-08-04 2007-02-15 Zymogenetics, Inc. Treatment of wounds using il-17b

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [online] EBI; 19 July 2005 (2005-07-19), XP002413790, Database accession no. Q9UHF5 *

Also Published As

Publication number Publication date
EP2089050A2 (en) 2009-08-19
WO2008073653A2 (en) 2008-06-19
JP2010509364A (en) 2010-03-25
CA2669109A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
WO2009040420A3 (en) Use of a monoterpene to increase tissue repair
NZ606825A (en) Methods and compositions for treating complement-associated disorders
WO2007002390A3 (en) Compositions and methods for modulation of smn2 splicing
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
NZ591338A (en) Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
WO2008045559A3 (en) Methods of treating oral mucositis
MX2010009623A (en) 1-benzyl-3-hydroxymethylindazoiî¹e derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1.
EP4327888A3 (en) Oral formulations of cytidine analogs and methods of use thereof
WO2009048778A3 (en) Laminins, derivatives, and compositions including same and method for their therapeutic use
WO2005094553A3 (en) Compositions for promoting bone growth and methods thereof
WO2009154840A3 (en) Compositions and methods using stem cells in cutaneous wound healing
WO2009158480A3 (en) Stimulation of cartilage formation using reduced pressure treatment and chondrocytes
WO2015009991A8 (en) Methods, systems, and compositions for promoting bone growth
WO2009079451A3 (en) Compositions and methods of promoting wound healing
MX2010009625A (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40.
WO2007100555A3 (en) Compositions containing lactoferrin, and methods of using same to promote growth of skin cells
WO2009022338A3 (en) Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
EP2407147A3 (en) Composition with bio-rigenerative, restorative and eutrophying activity
SE0102067D0 (en) Prevention of neovascularization of intervertebral discs and / or of tissues with local inflammation
EP4678173A3 (en) Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
EP3305305A3 (en) Silicate containing compositions and methods of treatment
EP1844779A3 (en) Tergurid/protergurid for treating chronic pain (e.g. migraine)
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
EP2316941A3 (en) Compositions and their uses directed to IL-4R alpha
WO2007019453A3 (en) Treatment of wounds using il-17b

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871415

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2009536488

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2669109

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007871415

Country of ref document: EP